#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)



## option care health<sup>®</sup>

## **OPTION CARE HEALTH, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u>

(State or other jurisdiction of incorporation)

<u>001-11993</u> (Commission File Number) <u>05-0489664</u> (IRS Employer Identification Number)

3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (Address of principal executive offices)

(312) 940-2443

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	OPCH	Nasdaq Global Select Market

#### Item 2.02. Results of Operations and Financial Condition.

On April 28, 2022, Option Care Health, Inc. issued a press release reporting its first quarter 2022 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits

 Exhibit No.
 Description

 99.1
 Press release dated April 28, 2022

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### Option Care Health, Inc.

Date: April 28, 2022

By: /s/ Michael Shapiro

Michael Shapiro Chief Financial Officer

Exhibit 99.1



# OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2022

**BANNOCKBURN, IL., April 28, 2022** - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced financial results for the first quarter ended March 31, 2022.

### First Quarter 2022 Financial Highlights

- Net revenue of \$915.8 million, up 20.6% compared to \$759.2 million in the first quarter of 2021
- Gross profit of \$200.9 million, or 21.9% of net revenue, up 21.4% compared to \$165.5 million, or 21.8% of revenue, in the first quarter of 2021
- Net income of \$30.3 million, or \$0.17 per share, compared to net loss of \$2.9 million, or \$0.02 loss per share, in the first quarter of 2021
- Adjusted EBITDA of \$77.8 million, up 48.9% compared to \$52.2 million in the first quarter of 2021
- Cash flow from operations of \$32.7 million compared \$18.4 million in the first quarter of 2021
- Cash balances of \$145.6 million at the end of the first quarter

John C. Rademacher, Chief Executive Officer, commented, "Despite a dynamic start to the year and ongoing pandemic disruption, the Option Care Health team executed exceptionally to ensure high quality patient care and solid financial results. Overall we expect 2022 to be a productive year as we continue to navigate a challenging environment and invest for future growth."

## Full Year 2022 Guidance

For the full year 2022, Option Care Health now expects to generate:

- Net Revenue of \$3.75 billion to \$3.90 billion
- Adjusted EBITDA of \$320 million to \$335 million
- Cash Flow from Operations of at least \$230 million

## **Conference Call**

The conference call can be accessed by dialing (866) 360-3136 and referencing conference ID 5737323; or via a live audio webcast that will be available online at <a href="https://investors.optioncarehealth.com">https://investors.optioncarehealth.com</a>. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

## **About Option Care Health**

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,000 teammates, including more than 4,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at <u>OptionCareHealth.com</u>.

## **Investor Contacts**

Mike Shapiro Chief Financial Officer T: (312) 940-2538 <u>mike.shapiro@optioncare.com</u> Bob East, Asher Dewhurst, Jordan Kohnstam Westwicke T: (413) 213-0500 <u>optioncarehealth@westwicke.com</u>

## Forward-Looking Statements - Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning our full year 2022 guidance and our expectations regarding industry and macroeconomic trends and our operating performance. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; and (iv) the loss of one or more key payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our most recent Annual Report on Form 10-K as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

## Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax

expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

#### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)

	(unaudited) March 31, 2022		December 31, 2021		
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	\$	145,600	\$	119,423	
Accounts receivable, net		366,285		338,242	
Inventories		217,184		183,095	
Prepaid expenses and other current assets		76,643		69,496	
Total current assets		805,712		710,256	
NONCURRENT ASSETS:					
Property and equipment, net		109,066		111,535	
Intangible assets, net		20,669		21,433	
Referral sources		337,882		344,587	
Goodwill		1,478,500		1,477,564	
Other noncurrent assets		126,447		125,543	
Total noncurrent assets		2,072,564		2,080,662	
TOTAL ASSETS	\$	2,878,276	\$	2,790,918	
LIABILITIES AND STOCKHOLDERS' EQUITY					
CURRENT LIABILITIES:					
Accounts payable	\$	356,118	\$	279,246	
Other current liabilities		152,021		180,449	
Total current liabilities		508,139		459,695	
NONCURRENT LIABILITIES:					
Long-term debt, net of discount, deferred financing costs and current portion		1,059,449		1,059,900	
Other noncurrent liabilities		88,924		95,437	
Total noncurrent liabilities		1,148,373		1,155,337	
Total liabilities		1,656,512		1,615,032	
STOCKHOLDERS' EQUITY		1,221,764		1,175,886	
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	2,878,276	\$	2,790,918	

#### OPTION CARE HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	Three Months	Three Months Ended		
	2022		2021	
NET REVENUE	\$ 915,784	\$	759,237	
COST OF REVENUE	714,848	i	593,764	
GROSS PROFIT	200,936	,	165,473	
OPERATING COSTS AND EXPENSES:				
Selling, general and administrative expenses	133,969	)	120,040	
Depreciation and amortization expense	14,722	1	16,339	
Total operating expenses	148,691		136,379	
OPERATING INCOME	52,245	<u> </u>	29,094	
OTHER INCOME (EXPENSE):				
Interest expense, net	(12,246	)	(19,481)	
Other, net	1,269		(11,196)	
Total other expense	(10,977	)	(30,677)	
INCOME (LOSS) BEFORE INCOME TAXES	41,268	3	(1,583)	
INCOME TAX EXPENSE	10,993	1	1,278	
NET INCOME (LOSS)	\$ 30,275	5 \$	(2,861)	
Formings (loss) new share basis and diluted	\$ 0.17	′\$	(0.02)	
Earnings (loss) per share, basic and diluted	φ 0.17	=	(0.02)	
Weighted average common shares outstanding, basic	179,961		179,808	
Weighted average common shares outstanding, diluted	181,681		179,808	

#### OPTION CARE HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)

	Three Months I	nths Ended March 31,	
	2022	2021	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income (loss)	\$ 30,275	\$ (2,861)	
Adjustments to reconcile net income (loss) to net cash provided by operations:			
Depreciation and amortization expense	15,979	17,716	
Other non-cash adjustments	21,131	18,196	
Changes in operating assets and liabilities:			
Accounts receivable, net	(28,766)	4,450	
Inventories	(34,089)	(15,021)	
Accounts payable	76,872	8,026	
Other	(48,721)	(12,126)	
Net cash provided by operating activities	32,681	18,380	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of property and equipment	(5,359)	(3,123)	
Net cash used in investing activities	(5,359)	(3,123)	
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from debt	—	355,200	
Retirement of debt obligations	—	(352,009)	
Other financing cash flows	(1,145)	(8,351)	
Net cash used in financing activities	(1,145)	(5,160)	
NET INCREASE IN CASH AND CASH EQUIVALENTS	26,177	10,097	
Cash and cash equivalents - beginning of the period	119,423	99,265	
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$ 145,600	\$ 109,362	

#### OPTION CARE HEALTH, INC. QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS) (UNAUDITED)

	Three Months Ended March 31,		
	2022		2021
Consolidated net income (loss)	\$ 30,275	\$	(2,861)
Interest expense, net	12,246		19,481
Income tax expense	10,993		1,278
Depreciation and amortization expense	15,979		17,716
Consolidated EBITDA	69,493		35,614
EBITDA adjustments			
Stock-based incentive compensation	4,178		1,205
Loss on extinguishment of debt	_		12,403
Restructuring, acquisition, integration and other	4,111		3,008
Consolidated adjusted EBITDA	\$ 77,782	\$	52,230